Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Vitamin D and Sexual Health (DASH)

This study has been completed.
Information provided by (Responsible Party):
Abigail Norris Turner, Ohio State University Identifier:
First received: October 7, 2011
Last updated: December 3, 2013
Last verified: December 2013
Bacterial vaginosis (BV) develops when the concentration of healthy Lactobacillus species in the vagina declines and is replaced by other bacterial species. BV is the most common vaginal infection worldwide, but the etiology of this complex condition is not clear. BV is associated with a 60% increased risk of HIV acquisition as well as numerous other detrimental reproductive outcomes. A profound racial disparity exists in BV prevalence in women in the United States (US): 23% of white women versus. 52% of black women have BV. The investigators hypothesize that inadequate vitamin D contributes to BV development and/or recurrence. Vitamin D is essential to immune function, serving both to stimulate mechanisms associated with pathogen elimination and to regulate immune response. According to nationally-representative data, 90% of US blacks have insufficient vitamin D levels. In two recent analyses, low vitamin D was associated with higher BV prevalence in pregnant African-Americans; a third replicated this finding in pregnant African-American and white women. The investigators wish to conduct a small, pilot randomized controlled trial (RCT) to assess the effect of vitamin D supplementation among non-pregnant, BV-positive women at a public sexually transmitted disease (STD) clinic. This small (n=150), two-arm, placebo-controlled, masked, 24-week RCT of high-dose vitamin D supplementation will inform the development of future large-scale RCT design and implementation.

Condition Intervention
Bacterial Vaginosis
Dietary Supplement: Vitamin D3 (cholecalciferol)
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Vitamin D and Sexual Health (the DASH Study)

Resource links provided by NLM:

Further study details as provided by Abigail Norris Turner, Ohio State University:

Primary Outcome Measures:
  • Serum vitamin D level [ Time Frame: 24 weeks ]
    To assess the effect of vitamin D supplementation on serum vitamin D levels after 24 weeks

  • Serum and cervical immunoinflammatory mediators [ Time Frame: 24 weeks ]
    To assess the effect of vitamin D supplementation on levels of and correlations between BV-associated and vitamin D-associated immunoinflammatory mediators after 24 weeks

  • Bacterial vaginosis recurrence [ Time Frame: 24 weeks ]
    To assess the effect of high-dose vitamin D on recurrence of bacterial vaginosis

Enrollment: 118
Study Start Date: September 2011
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vitamin D (cholecalciferol) Dietary Supplement: Vitamin D3 (cholecalciferol)
Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
Placebo Comparator: Placebo Dietary Supplement: Placebo
Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • speak English;
  • be between 18 and 50 years old, inclusive;
  • be pre-menopausal;
  • have at least one ovary;
  • be positive for bacterial vaginosis

Exclusion Criteria:

  • pregnant at enrollment or in the previous 3 months;
  • planning to become pregnant in the next six months;
  • currently breastfeeding;
  • currently be menstruating heavily;
  • have a contraindication to oral metronidazole treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01450462

United States, Ohio
Columbus Public Health Sexual Health Clinic
Columbus, Ohio, United States, 43215
Sponsors and Collaborators
Ohio State University
Principal Investigator: Abigail Norris Turner, PhD Assistant Professor
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Abigail Norris Turner, Assistant Professor, Ohio State University Identifier: NCT01450462     History of Changes
Other Study ID Numbers: KL2RR025754-ANT
KL2RR025754 ( US NIH Grant/Contract Award Number )
Study First Received: October 7, 2011
Last Updated: December 3, 2013

Additional relevant MeSH terms:
Vaginosis, Bacterial
Bacterial Infections
Vaginal Diseases
Genital Diseases, Female
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on May 25, 2017